Polymorphisms in NFKBIA may be important in pre-disposition to and outcome after treatment, of multiple myeloma (MM). The NFKBIA gene product, IkappaBalpha, binds to NF-kappaB preventing its activation and is important in mediating resistance to apoptosis in B-cell lymphoproliferative diseases. This study investigates eight polymorphisms across the NFKBIA gene in large patient and control populations. Significant differences in the frequency of particular polymorphisms were noted between patients and controls. A risk haplotype [GCCTATCA] for MM was also identified (P=0.006). Analysis of the genetics of NFKBIA may lead to associations with disease progression and survival and thus more personalized therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.canlet.2006.02.001 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!